BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35930109)

  • 1. Impact of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer with Peritoneal Carcinomatosis: A Systematic Review and Meta-analysis.
    Martins M; Santos-Sousa H; Araújo F; Nogueiro J; Sousa-Pinto B
    Ann Surg Oncol; 2022 Nov; 29(12):7528-7537. PubMed ID: 35930109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
    Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
    World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis].
    Liu D; Wang H; Yuan ZX; Chen WW; Wu ZJ; Liu XX; Luo J; Chu LL; Li Y; Cai J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):256-263. PubMed ID: 34645170
    [No Abstract]   [Full Text] [Related]  

  • 4. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
    Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
    [No Abstract]   [Full Text] [Related]  

  • 5. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
    Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
    Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Cancers with Peritoneal Metastasis: A 30-year Institutional Experience.
    Valenzuela CD; Levine EA; Mangieri CW; Gawdi R; Moaven O; Russell G; Lundy ME; Perry KC; Votanopoulos KI; Shen P
    Ann Surg Oncol; 2022 Jun; 29(6):3436-3445. PubMed ID: 35286531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups.
    Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F
    BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Laparoscopy in Patients With Peritoneal Carcinomatosis Is Safe and Does Not Delay Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy.
    Hanna DN; Ghani MO; Hermina A; Mina A; Bailey CE; Idrees K; Magge D
    Am Surg; 2022 Apr; 88(4):698-703. PubMed ID: 34732056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments.
    Santullo F; Ferracci F; Abatini C; Halabieh MAE; Lodoli C; D'Annibale G; Di Cesare L; D'Agostino L; Pecere S; Di Giorgio A; Strippoli A; Pacelli F
    Langenbecks Arch Surg; 2023 Nov; 408(1):437. PubMed ID: 37973620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis from gastric cancer: a clinical study of 110 patients].
    Ji ZH; Li XB; Liu G; Yu Y; Lin YL; Zhang YB; Li Y
    Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3079-3083. PubMed ID: 30392267
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy.
    Zhou S; Jiang Y; Liang J; Pei W; Zhou Z
    World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The robotic future of minimally invasive cytoreduction and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies.
    Ortega J; Orfanelli T; Levine E; Konstantinidis IT
    Chin Clin Oncol; 2023 Apr; 12(2):16. PubMed ID: 36946185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
    Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P
    World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complexity of surgery and treatment burden in patients with peritoneal malignancy is not determined by addition of hyperthermic intraperitoneal chemotherapy.
    Steffens D; Ansari N; Koh C; Ahmadi N; Solomon MJ; Hogan S; Karunaratne S; Anderson T; Harvey K; McBride K; Moran B
    ANZ J Surg; 2024 Apr; 94(4):628-633. PubMed ID: 38450829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience.
    Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S
    Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy Followed by Cytoreductive Surgery and HIPEC Improves Survival in Peritoneal Metastatic Gastric Cancer.
    Akturk Esen S; Ozgun YM; Hasturk D; Ucar G; Bostanci EB; Sendur MAN; Uncu D
    Oncology; 2023; 101(5):321-327. PubMed ID: 36809752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP).
    Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J
    Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: Propensity score-matched comparison between laparoscopy vs. open approaches.
    Chang SC; Fingerhut A; Chen WT
    Surg Oncol; 2022 Aug; 43():101766. PubMed ID: 35430126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.